Novo no show for Tresiba in Germany
This article was originally published in Scrip
It's too big a risk for Novo Nordisk to launch its diabetes drug Tresiba (insulin degludec) in Germany thanks to the AMNOG pricing and reimbursement system, said the firm's vice president of marketing and medical affairs, Jacob Riis. Novo Nordisk believes that it would have to sacrifice too much on price. "Even though we have the documentation, both clinically and from a health economics point of view, we are not convinced the German authorities will acknowledge the benefits of Tresiba, " said Mr Riis.
You may also be interested in...
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.
Insurers argue that better use of real world data and multiple pricing assessments could help lower drug prices in Germany.
To keep investors happy, companies will have to start showing that their high-priced advanced therapies offset costs elsewhere in the health care system.